TY - JOUR
T1 - Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients
T2 - A multicentric retrospective analysis
AU - Silvestris, Nicola
AU - Scartozzi, Mario
AU - Graziano, Giusi
AU - Santini, Daniele
AU - Lorusso, Vito
AU - Maiello, Evaristo
AU - Barni, Sandro
AU - Cinieri, Saverio
AU - Loupakis, Fotios
AU - Pisconti, Salvatore
AU - Brunetti, Anna Elisabetta
AU - Palasciano, Giuseppe
AU - Palmieri, Vincenzo Ostilio
AU - Del Prete, Michela
AU - Dell'Aquila, Emanuela
AU - Latiano, Tiziana Pia
AU - Petrelli, Fausto
AU - Lutrino, Stefania
AU - Rossini, Daniele
AU - Giampieri, Riccardo
AU - Lotesoriere, Claudio
AU - Cascinu, Stefano
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background: To assess the predictive role of lactate dehydrogenases (LDH) and fibrinogen (FBG) serum levels in metastatic colorectal cancer (mCRC) patients receiving a first-line bevacizumab-based therapy.Objectives: The aim of the present analysis was to retrospectively evaluate the role of basal and post-treatment LDH and FBG serum levels in predicting the clinical outcome of 139 mCRC patients receiving first-line chemotherapy in combination with bevacizumab.Results: A statistically significant association between high pre-treatment LDH and FBG levels and progressive disease was observed with respect to low basal LDH and FBG patients. Furthermore, median progression-free survival was 7.3 versus 10.8 months and 7.3 versus 9.4 months for high and low LDH and FBG levels, respectively. Within the high LDH group, we observed a statistically significant reduction of LDH mean value compared with pre-treatment values in patients with objective response rate and stable disease.Conclusions: High LDH and FBG levels correlated with prognosis. A significant correlation between bevacizumab-based chemotherapy-induced reduction in LDH serum levels and response to treatment was observed within the high LDH group. These results, if confirmed in larger prospective studies, could be helpful for early identification of patients responsive to bevacizumab-based chemotherapy or candidate to more aggressive treatments.
AB - Background: To assess the predictive role of lactate dehydrogenases (LDH) and fibrinogen (FBG) serum levels in metastatic colorectal cancer (mCRC) patients receiving a first-line bevacizumab-based therapy.Objectives: The aim of the present analysis was to retrospectively evaluate the role of basal and post-treatment LDH and FBG serum levels in predicting the clinical outcome of 139 mCRC patients receiving first-line chemotherapy in combination with bevacizumab.Results: A statistically significant association between high pre-treatment LDH and FBG levels and progressive disease was observed with respect to low basal LDH and FBG patients. Furthermore, median progression-free survival was 7.3 versus 10.8 months and 7.3 versus 9.4 months for high and low LDH and FBG levels, respectively. Within the high LDH group, we observed a statistically significant reduction of LDH mean value compared with pre-treatment values in patients with objective response rate and stable disease.Conclusions: High LDH and FBG levels correlated with prognosis. A significant correlation between bevacizumab-based chemotherapy-induced reduction in LDH serum levels and response to treatment was observed within the high LDH group. These results, if confirmed in larger prospective studies, could be helpful for early identification of patients responsive to bevacizumab-based chemotherapy or candidate to more aggressive treatments.
KW - Bevacizumab
KW - Clinical outcome
KW - Colorectal carcinoma
KW - Fibrinogen
KW - Lactate dehydrogenases
UR - http://www.scopus.com/inward/record.url?scp=84920989784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920989784&partnerID=8YFLogxK
U2 - 10.1517/14712598.2015.986452
DO - 10.1517/14712598.2015.986452
M3 - Article
C2 - 25411089
AN - SCOPUS:84920989784
VL - 15
SP - 155
EP - 162
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 2
ER -